STAT

At first-ever public hearing on CBD, advocates and FDA try to blaze trail to regulatory compromise

What happens when you put hemp farmers, moms against pot, and Ph.D. scientists in a room to discuss #CBD?
Candy made with cannabidiol, or CBD. Source: Jeremy Rehm/AP

SILVER SPRING, Md. — By 10:30 a.m., a panel of the Food and Drug Administration’s top regulators had already heard from more than 50 different people, all eager to squeeze their hopes or concerns about CBD, the booming marijuana-adjacent compound companies are suddenly adding to everything from dog food to dietary supplements, into the short speaking time they were granted.

There were mothers claiming marijuana drove their children to suicide, millennial entrepreneurs who struggled for a good answer

You're reading a preview, sign up to read more.

More from STAT

STAT2 min readPolitics
Biden Puts Forth An Elaborate — And Aggressive — Plan To Lower Drug Prices
His new platform includes some of the most aggressive approaches to lowering drug prices any Democratic presidential candidate has proposed to date. 
STAT10 min readPolitics
How Pharma, Under Attack From All Sides, Keeps Winning In Washington
It’s all President Trump and Democrats on Capitol Hill can agree on. So why hasn’t Washington lowered drug prices?
STAT3 min read
Opinion: I Get Asked A Lot About Longevity. It Helps That I’m 104
As scientists pursue longevity and anti-aging research, we wanted to hear from a centenarian on her life experience and thoughts on aging. So we called one.